Scott+Scott, Attorneys at Law, LLP Announces Investigation of Kadmon Holdings Inc. (KDMN)

NEW YORK, May 16, 2017 /PRNewswire/ -- Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, has commenced an investigation into Kadmon Holdings Inc. (NYSE: KDMN) ("Kadmon" or the "Company") related to potential violations of federal securities laws.  If you are a Kadmon shareholder, you are encouraged to contact Scott+Scott for additional information.

Kadmon operates as a biopharmaceutical company.  The Company engages in the discovery, development, and commercialization of small molecules and biologics to address disease areas of significant unmet medical need.

Scott+Scott's investigation focuses on Kadmon's "co-promotion" relationship with Valeant Pharmaceuticals, which saw its former employees charged with fraud in November 2016.

Kadmon held its Initial Public Offering ("IPO") on July 27, 2016, with its shares priced at $12.00.  Since the IPO, Kadmon's share price has plummeted to under $3 per share – a drop of over 75%.

What You Can Do

If you are a Kadmon shareholder and you wish to discuss this investigation, or if you have questions about this notice or your legal rights, please contact attorney Rhiana Swartz at (844) 818-6980, or at [email protected].

About Scott+Scott, Attorneys at Law, LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.  The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California and Ohio.

CONTACT:
Rhiana Swartz
Scott+Scott, Attorneys at Law, LLP 
(844) 818-6980
[email protected] 

SOURCE Scott+Scott, Attorneys at Law, LLP

Related Links

http://scott-scott.com